Physician profile
James D Briggs
NPI 1811996358
$1,791.69
in general payments reported to CMS, 2019-2025
32 companies · $21.00 in 2025
The $21.00 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $208 · 2021: $664 · 2022: $65.60 · 2024: $33.60 · 2025: $21.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $54.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $54.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $522.15 | 2019-2022 | |
| Pfizer INC. | $148.61 | 2019 | |
| Urovant Sciences INC | $122.17 | 2021-2022 | |
| Boston Scientific Corporation | $90.15 | 2019-2025 | General - Female Sui |
| Bayer Healthcare Pharmaceuticals INC. | $89.11 | 2019-2021 | |
| Coloplast Corp | $84.81 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $78.79 | 2021 | |
| Axonics, INC. | $64.46 | 2020-2022 | |
| 180 Medical, INC. | $50.23 | 2019-2021 | |
| Urogen Pharma, INC. | $45.87 | 2021 | |
| Janssen Biotech, INC. | $45.09 | 2019 | |
| Zyla Life Sciences, INC. | $43.99 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $43.91 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $41.66 | 2019 | |
| Rochester Medical Corporation | $34.76 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $31.73 | 2020-2021 | |
| Olympus America INC. | $28.86 | 2019 | |
| Cook Medical LLC | $27.72 | 2021-2024 | Resonance |
| Blue Earth Diagnostics | $25.10 | 2021 | |
| Dornier Medtech America, INC | $18.57 | 2019 | |
| Merck Sharp & Dohme LLC | $18.23 | 2024 | Keytruda, Welireg |
| Myriad Genetic Laboratories, INC. | $16.13 | 2021 | |
| Therapeuticsmd, INC. | $15.18 | 2019 | |
| Axogen | $14.64 | 2019 | |
| Neotract INC. | $13.86 | 2019 | |
| Duchesnay USA Incorporated | $13.31 | 2019 | |
| Medtronic USA, INC. | $13.31 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.89 | 2019 | |
| Shire North American Group INC | $11.56 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $11.47 | 2019 | |
| Medtronic, INC. | $11.30 | 2021 | |
| Clarus Therapeutics INC. | $3.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.